Global Blood Therapeutics Inc. announced that the World Health Organization (WHO) has approved voxelotor as the International Nonproprietary Name (INN) for its lead product candidate GBT440, and that the United States Adopted Name Council has adopted voxelotor as the United States Adopted Name (USAN) for GBT440. Voxelotor is an oral, once-daily therapy that is designed to modulate hemoglobin affinity for oxygen and is in clinical development for the treatment of sickle cell disease (SCD).